Literature DB >> 15197640

Plasmapheresis therapy for rapidly progressive Henoch-Schönlein nephritis.

Yukihiko Kawasaki1, Junzo Suzuki, Michihiko Murai, Ai Takahashi, Masato Isome, Ruriko Nozawa, Shigeo Suzuki, Hitoshi Suzuki.   

Abstract

Six Japanese children with rapidly progressive Henoch-Schönlein purpura nephritis (HSPN) received multiple drug therapy combined with plasmapheresis (PP). After five courses of PP, multiple drug therapy, including methylprednisolone and urokinase pulse therapy, oral prednisolone, cyclophophamide, dipyridamole, and warfarin was given. At presentation, urine protein excretion and histological indices of the mean activity and chronicity were 245+/-101 mg/m(2) per hour, 6.6+/-1.2, and 1.5+/-1.3, respectively. After 6 months of therapy, urinary protein excretion had decreased significantly ( P<0.001). The activity index decreased significantly at the second renal biopsy performed at a mean interval of 4.3 months after the first (2.8+/-1.4, P<0.05), while the chronicity index did not change. At the most recent observation, all showed clinical improvement. Two patients had normal urine, three had proteinuria of <20 mg/m(2) per hour, one had proteinuria of >20 mg/m(2) per hour, and none had renal insufficiency. Although this case series is without controls, our treatment protocol may be of benefit to children with rapidly progressive HSPN.

Entities:  

Mesh:

Year:  2004        PMID: 15197640     DOI: 10.1007/s00467-004-1514-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  9 in total

1.  THE PATHOGENIC ROLE OF FIBRIN DEPOSITION IN IMMUNOLOGICALLY INDUCED GLOMERULONEPHRITIS.

Authors:  P VASSALLI; R T MCCLUSKEY
Journal:  Ann N Y Acad Sci       Date:  1964-08-27       Impact factor: 5.691

2.  Prognosis of Henoch-Schönlein nephritis in children.

Authors:  R Counahan; M H Winterborn; R H White; J M Heaton; S R Meadow; N H Bluett; H Swetschin; J S Cameron; C Chantler
Journal:  Br Med J       Date:  1977-07-02

3.  Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis.

Authors:  Yukihiko Kawasaki; Junzo Suzuki; Ruriko Nozawa; Shigeo Suzuki; Hitoshi Suzuki
Journal:  Pediatrics       Date:  2003-04       Impact factor: 7.124

4.  Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schönlein purpura nephritis in children.

Authors:  M Hattori; K Ito; T Konomoto; H Kawaguchi; T Yoshioka; M Khono
Journal:  Am J Kidney Dis       Date:  1999-03       Impact factor: 8.860

5.  Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis.

Authors:  A Gianviti; R S Trompeter; T M Barratt; M F Lythgoe; M J Dillon
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

6.  Treatment of severe IgA nephropathy in children.

Authors:  S P Andreoli; J M Bergstein
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  Long-term effect of urokinase therapy in IgA nephropathy.

Authors:  M Miura; M Endoh; Y Nomoto; H Sakai
Journal:  Clin Nephrol       Date:  1989-11       Impact factor: 0.975

8.  Multiple combined therapy for severe Henoch-Schönlein nephritis in children.

Authors:  K Iijima; S Ito-Kariya; H Nakamura; N Yoshikawa
Journal:  Pediatr Nephrol       Date:  1998-04       Impact factor: 3.714

9.  Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis.

Authors:  P Niaudet; R Habib
Journal:  Pediatr Nephrol       Date:  1998-04       Impact factor: 3.714

  9 in total
  18 in total

Review 1.  Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.

Authors:  Marco Zaffanello; Vassilios Fanos
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

2.  Successful treatment of gastrointestinal involvement in Henoch-Schönlein purpura with plasmapheresis.

Authors:  Banu Acar; F Inci Arikan; Bulent Alioglu; Nergis Oner; Yildiz Dallar
Journal:  Pediatr Nephrol       Date:  2008-06-11       Impact factor: 3.714

Review 3.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

4.  Childhood vasculitis and plasma exchange.

Authors:  Elizabeth Wright; Michael J Dillon; Kjell Tullus
Journal:  Eur J Pediatr       Date:  2006-08-17       Impact factor: 3.183

5.  Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome.

Authors:  Shinichiro Ohara; Yukihiko Kawasaki; Hiromi Matsuura; Tomoko Oikawa; Kazuhide Suyama; Mitsuaki Hosoya
Journal:  Clin Exp Nephrol       Date:  2011-05-28       Impact factor: 2.801

6.  Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity.

Authors:  Takeshi Ninchoji; Hiroshi Kaito; Kandai Nozu; Yuya Hashimura; Kyoko Kanda; Ichiro Kamioka; Yuko Shima; Kiyoshi Hamahira; Koichi Nakanishi; Ryojiro Tanaka; Norishige Yoshikawa; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2011-01-04       Impact factor: 3.714

7.  Factors affecting histological regression of crescentic Henoch-Schönlein nephritis in children.

Authors:  Jae Il Shin; Jee Min Park; Ji Hong Kim; Jae Seung Lee; Hyeon Joo Jeong
Journal:  Pediatr Nephrol       Date:  2005-11-04       Impact factor: 3.714

Review 8.  Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.

Authors:  Jun-Yi Chen; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2014-12-29       Impact factor: 2.764

9.  Plasmapheresis therapy in an elderly patient with rapidly progressive Henoch-Schönlein purpura with disseminated organ involvement.

Authors:  J Rech; F Fuchs; S Kallert; A J Hueber; C Requadt; B Manger; J R Kalden; K Amann; R Strauss; H Schulze-Koops
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

Review 10.  The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis.

Authors:  Yukihiko Kawasaki
Journal:  Clin Exp Nephrol       Date:  2011-06-23       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.